血清CX3CL1在肺癌骨转移中的临床意义

doi:10.3969/j.issn.1673-8640.2018.04.005

摘要/Abstract

摘要：

目的探讨CX3趋化因子配体1（CX3CL1）在肺癌骨转移患者中的临床意义。方法采用酶联免疫吸附试验（ELISA）检测40例肺癌骨转移患者（骨转移组）及40例无远处转移的肺癌患者（无转移组）的血清CX3CL1水平。80例肺癌患者中腺癌57例、鳞癌23例。结合患者临床病理资料,回顾性分析各组血清CX3CL1水平的差异。结果骨转移组血清CX3CL1水平为（0.69±0.09）ng/mL,高于无转移组[（0.62±0.06）ng/mL]（P<0.001）。57例腺癌患者中,33例骨转移患者血清CX3CL1水平[（0.68±0.09）ng/mL]高于24例无转移患者[（0.61±0.06）ng/mL]（P=0.002）;在23例鳞癌中,7例骨转移患者血清CX3CL1水平[（0.74±0.05）ng/mL]高于16例无转移患者[（0.63±0.07）ng/mL]（P<0.05）。不同病理类型、原发灶大小、年龄和性别的肺癌患者之间血清CX3CL1水平差异均无统计学意义（P>0.05）。结论血清CX3CL1水平有望成为监测肺癌骨转移的一个辅助指标。

关键词: CX3趋化因子配体1, 肺癌, 腺癌, 鳞癌, 骨转移

Abstract:

Objective To investigate the role of serum CX3 chemokine ligand 1（CX3CL1） in bone metastatic lung cancer patients. Methods A total of 40 lung cancer patients with bone metastasis and 40 lung cancer patients without distant metastasis（control group） were enrolled. Serum CX3CL1 expression was determined in 80 lung cancer patients（57 cases of adenocarcinoma and 23 cases of squamous carcinoma） by enzyme-linked immunosorbent assay（ELISA）. Combined with clinicopathologic analysis,the difference of serum CX3CL1 expression levels was analyzed retrospectively. Results Serum CX3CL1 expression level in metastasis group [（0.69±0.09） ng/mL] was higher than that in non-metastasis group [（0.62±0.06）ng/mL]（P<0.001）. Among 57 adenocarcinoma cases,serum CX3CL1 expression level in metastasis group （33 cases）[（0.68±0.09）ng/mL] was higher than that in non-metastasis group（24 cases） [（0.61±0.06）ng/mL]（P=0.002）. Among 23 squamous carcinoma cases,serum CX3CL1 expression level in metastasis group （7 cases）[（0.74±0.05）ng/mL] was higher than that in non-metastasis group（16 cases）[（0.63±0.07）ng/mL]（P<0.05）. The difference of serum CX3CL1 expression with different primary lesion sizes,ages and sex had no statistical significance（P>0.05）. Conclusions Serum CX3CL1 could be used as an independent marker for predicting bone metastasis in lung cancer patients.

Key words: CX3 chemokine ligand 1, Lung cancer, Adenocarcinoma, Squamous carcinoma, Bone metastasis

中图分类号:

R446.1

许晨, 唐晓峰. 血清CX3CL1在肺癌骨转移中的临床意义[J]. 检验医学, 2018, 33(4): 295-298.

XU Chen, TANG Xiaofeng. Role of serum CX3CL1 in bone metastatic lung cancer[J]. Laboratory Medicine, 2018, 33(4): 295-298.

图/表 3

参考文献 11

[1]	JEMAL A,BRAY F,CENTER M M,et al.Global cancer statistics[J]. CA Cancer J Clin,2011,61(2):69-90.
[2]	赫捷,陈万青. 2012中国肿瘤登记年报[M]. 北京:军事医学科学出版社,2012:10-11.
[3]	GUPTA G P,MASSAGUÉ J.Cancer metastasis:building a framework[J]. Cell,2006,127(4):679-695.
[4]	SUGIURA H,YAMADA K,SUGIURA T,et al.Predictors of survival in patients with bone metastasis of lung cancer[J]. Clin Orthop Relat Res,2008,466(3):729-736.
[5]	TSUKUSHI S,KATAGIRI H,KATAOKA T,et al.Serum tumor markers in skeletal metastasis[J]. Jpn J Clin Oncol,2006,36(7):439-444.
[6]	LIU W,BIAN C,LIANG Y,et al.CX3CL1:a potential chemokine widely involved in the process spinal metastases[J]. Oncotarget,2017,8(9):15213-15219.
[7]	COLEMAN R E.Skeletal complications of malignancy[J]. Cancer,1997,80(8 Suppl):1588-1594.
[8]	SIEGEL R,DESANTIS C,VIRGO K,et al.Cancer treatment and survivorship statistics,2012[J]. CA Cancer J Clin,2012,62(4):220-241.
[9]	DABROWSKA M,GRUBEK-JAWORSKA H,DOMAGAA-KULAWIK J,et al.Diagnostic usefulness of selected tumor markers(CA125,CEA,CYFRA 21-1) in bronchoalveolar lavage fluid in patients with non-small cell lung cancer[J]. Pol Arch Med Wewn,2004,111(6):659-665.
[10]	LUSTER A D.Chemokines-chemotactic cytokines that mediate inflammation[J]. N Engl J Med,1998,338(7):436-445.
[11]	CAI X,LUO J,YANG X,et al.In vivo selection for spine-derived highly metastatic lung cancer cells is associated with increased migration,inflammation and decreased adhesion[J]. Oncotarget,2015,6(26):22905-22917.

因素	例数	CX3CL1
年龄（岁）
>68	40	0.67±0.10
≤68	40	0.64±0.07
性别
男	44	0.67±0.08
女	36	0.64±0.08
转移情况
骨转移	40	0.69±0.09
无转移	40	0.62±0.06^*
病理类型
腺癌	57	0.65±0.09
鳞癌	23	0.66±0.08
原发灶直径（cm）
>1.31	40	0.67±0.09
≤1.31	40	0.65±0.08

因素	例数	CX3CL1
年龄（岁）
>68	40	0.67±0.10
≤68	40	0.64±0.07
性别
男	44	0.67±0.08
女	36	0.64±0.08
转移情况
骨转移	40	0.69±0.09
无转移	40	0.62±0.06^*
病理类型
腺癌	57	0.65±0.09
鳞癌	23	0.66±0.08
原发灶直径（cm）
>1.31	40	0.67±0.09
≤1.31	40	0.65±0.08

因素	例数	CX3CL1
年龄（岁）
>67	28	0.67±0.10
≤67	29	0.64±0.07
性别
男	30	0.66±0.08
女	27	0.64±0.09
转移情况
骨转移	33	0.68±0.09
无转移	24	0.61±0.06^*
原发灶直径（cm）
>1.32	29	0.65±0.09
≤1.32	28	0.65±0.09

因素	例数	CX3CL1
年龄（岁）
>67	28	0.67±0.10
≤67	29	0.64±0.07
性别
男	30	0.66±0.08
女	27	0.64±0.09
转移情况
骨转移	33	0.68±0.09
无转移	24	0.61±0.06^*
原发灶直径（cm）
>1.32	29	0.65±0.09
≤1.32	28	0.65±0.09

因素	例数	CX3CL1
年龄（岁）
>72	12	0.67±0.07
≤72	11	0.66±0.09
性别
男	14	0.68±0.09
女	9	0.65±0.06
转移情况
骨转移	7	0.74±0.05
无转移	16	0.63±0.07^*
原发灶直径（cm）
>1.29	11	0.69±0.08
≤1.29	12	0.64±0.08